Page last updated: 2024-12-07

fluazifop

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluazifop is a selective post-emergence herbicide that is used to control annual and perennial grasses in broadleaf crops. It is a member of the aryloxyphenoxypropionate (AOPP) family of herbicides. Fluazifop works by inhibiting the biosynthesis of fatty acids in plants, specifically the enzyme acetyl-CoA carboxylase (ACCase). This enzyme is essential for the production of fatty acids, which are necessary for cell membrane formation and other important functions. When ACCase is inhibited, the plant is unable to produce the fatty acids it needs, and it eventually dies. Fluazifop is effective in controlling a wide range of grass weeds, including wild oats, foxtail, and barnyard grass. It is used in a variety of crops, including soybeans, corn, and wheat. Fluazifop is a non-systemic herbicide, meaning that it is absorbed mainly by the leaves of the plant and does not move throughout the plant. It is generally applied as a foliar spray and is readily absorbed by the leaves of weeds. Fluazifop has a relatively long half-life in the soil and can persist for several months. It can be degraded by soil microorganisms, but it can also volatilize into the air. The mode of action of fluazifop, inhibiting ACCase, is shared with other AOPP herbicides, making it possible to develop resistance to this class of herbicides. Therefore, it is essential to use fluazifop in an integrated weed management program to prevent the development of resistance. Fluazifop is an important herbicide for controlling weeds in agricultural crops. Its selectivity and effectiveness make it a valuable tool for farmers. However, it is important to use fluazifop responsibly and to follow label instructions carefully to minimize the risk of environmental contamination and to prevent the development of herbicide resistance.'

fluazifop: RN given for parent cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluazifop : A racemate comprising equimolar amounts of (R)-fluazipop (the active enantiomer, also known as fluazifop-P) and (S)-fluazifop (the inactive enantiomer). Both fluazifop and fluazifop-P have been used (generally as the corresponidng n-butyl esters, known as fluazifop-butyl and fluazifop-P-butyl, respectively) as herbicides for the pre-emergence control of grass weeds in a variety of crops. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-(4-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid : A monocarboxylic acid that is propanoic acid substituted by a 4-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID91701
CHEMBL ID376218
CHEBI ID83598
SCHEMBL ID67403
MeSH IDM0144341

Synonyms (31)

Synonym
fluazifop
2-[4-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenoxy]propanoic acid
69335-91-7
(+-)-2-(4-((5-(trifluoromethyl)-2-pyridinyl)oxy)phenoxy)propanoic acid
(rs)-2-(4-(5-trifluoromethyl-2-pyridyloxy)phenoxy)propionic acid
propanoic acid, 2-(4-((5-(trifluoromethyl)-2-pyridinyl)oxy)phenoxy)-
fluazifop [ansi:bsi:iso]
chebi:83598 ,
CHEMBL376218
2-[4-[5-(trifluoromethyl)pyridin-2-yl]oxyphenoxy]propanoic acid
C18527
8jd49yw45k ,
unii-8jd49yw45k
2-[4-(5-trifluoromethyl-2-pyridyloxy)phenoxy]propionic acid
SCHEMBL67403
2-(4-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid
DTXSID3058163
(rs)-(+)-2-[4-(5-trifluoromethyl-2-pyridyloxy)phenoxy]propionic acid
fluazifop [iso]
121958-44-9
mfcd00270159
fluazifop, pestanal(r), analytical standard
fluazifop (free acid)
fluazifop (free acid) 100 microg/ml in acetonitrile
Q27156995
(+/-)-fluazifop-d4
(+/-)-fluazifop
CS-0082015
propanoic acid, 2-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy]-
EN300-22540783
Z361128952

Research Excerpts

Overview

Fluazifop is a grass-selective herbicide that appears to act by inhibiting fatty acid synthesis de novo.

ExcerptReferenceRelevance
"Fluazifop is a grass-selective herbicide that appears to act by inhibiting fatty acid synthesis de novo in sensitive species. "( Fluazifop, a grass-selective herbicide which inhibits acetyl-CoA carboxylase in sensitive plant species.
Harwood, JL; Lewis, T; Ridley, SM; Walker, KA, 1988
)
3.16

Pharmacokinetics

The excretion rate of the principal metabolite fluazifop, following dosing with the 5% formulation, was described by a two-compartment pharmacokinetic model. The average elimination half-lives of initial and terminal phases were 18 h and approximately 70 h, respectively.

ExcerptReferenceRelevance
" Urinary excretion rate of the principal metabolite fluazifop, following dosing with the 5% formulation, was described by a two-compartment pharmacokinetic model; the average elimination half-lives of initial and terminal phases were 18 h and approximately 70 h, respectively."( Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.
Auton, TR; Batten, PL; Leeser, JE; Ramsey, JD; Woollen, BH, 1992
)
0.86

Bioavailability

ExcerptReferenceRelevance
" It is concluded that fluazifop-butyl is only slowly and poorly absorbed through human skin and has a low potential to accumulate in man."( Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.
Auton, TR; Batten, PL; Leeser, JE; Ramsey, JD; Woollen, BH, 1992
)
0.92

Dosage Studied

ExcerptRelevanceReference
" Urinary excretion rate of the principal metabolite fluazifop, following dosing with the 5% formulation, was described by a two-compartment pharmacokinetic model; the average elimination half-lives of initial and terminal phases were 18 h and approximately 70 h, respectively."( Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.
Auton, TR; Batten, PL; Leeser, JE; Ramsey, JD; Woollen, BH, 1992
)
0.86
" Dose-response assay indicated a resistance factor of 87."( Molecular basis for resistance to ACCase-inhibiting fluazifop in Eleusine indica from Malaysia.
Cha, TS; Chuah, TS; Najihah, MG; Sahid, IB, 2014
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monocarboxylic acidAn oxoacid containing a single carboxy group.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID278577Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID278576Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (20.00)18.7374
1990's13 (37.14)18.2507
2000's5 (14.29)29.6817
2010's9 (25.71)24.3611
2020's1 (2.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.75 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index101.75 (26.88)
Search Engine Supply Index3.88 (0.95)

This Compound (38.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]